CLINICAL_TRIALS
trial_result
· 2014-06-06
Clinical Trial Update: Safety, Clinical Tolerability and Immunogenicity of Increasing Doses of gpASIT+TM [Phase 2]
Summary
Phase 2 trial assessing safety, tolerability, and immunogenicity of escalating doses of gpASIT+TM in hay fever patients.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: BioTech Tools S.A. | Conditions: Hay Fever | Phase 2 | Status: COMPLETED